SMARCA4 and non-small cell lung carcinoma: The literature review revealed only 2 other documented cases of NSCLC with concurrent SMARCA4 deficiency and EGFR or ALK mutations, complicating the ability to draw definitive conclusions regarding optimal treatment strategies for this specific subgroup.